 |
29 Diseases |  |
0 Trials |
|
0 Trials |  |
38 News |  |
- | ifabotuzumab (KB004) / Humanigen
Journal: Antibody-mediated depletion of CCR10+ EphA3+ cells ameliorates fibrosis in IPF. (Pubmed Central) - Feb 15, 2022
Ifabotuzumab-targeted killing of EphA3+ cells significantly reduced the numbers of CCR10+ cells and ameliorated pulmonary fibrosis in humanized NSG mice. Thus, human CCR10+ cells promote pulmonary fibrosis and EphA3 mAb-directed elimination of these cells inhibits lung fibrosis.
- || ifabotuzumab (KB004) / Humanigen
Trial completion: A Trial of KB004 in Patients With Glioblastoma (clinicaltrials.gov) - Nov 4, 2021
P1, N=12, Completed, Sponsor: Olivia Newton-John Cancer Research Institute
Thus, human CCR10+ cells promote pulmonary fibrosis and EphA3 mAb-directed elimination of these cells inhibits lung fibrosis. Active, not recruiting --> Completed
- | ifabotuzumab (KB004) / Humanigen
Trial completion date: A Trial of KB004 in Patients With Glioblastoma (clinicaltrials.gov) - Jun 30, 2021
P1, N=12, Active, not recruiting, Sponsor: Olivia Newton-John Cancer Research Institute
Active, not recruiting --> Completed Trial completion date: Apr 2021 --> Sep 2021
- ifabotuzumab (KB004) / Humanigen
[VIRTUAL] Phase I safety and bioimaging trial of ifabotuzumab in patients with glioblastoma. () - Mar 11, 2021 - Abstract #AACR2021AACR_2545;
The imaging changes suggest direct modulation of the tumor vasculature. Additional studies are planned to evaluate ifabotuzumab as part of an antibody-drug conjugate in various solid tumor types.
- || ifabotuzumab (KB004) / Humanigen
Enrollment closed, Trial primary completion date: A Trial of KB004 in Patients With Glioblastoma (clinicaltrials.gov) - Dec 9, 2020
P1, N=12, Active, not recruiting, Sponsor: Olivia Newton-John Cancer Research Institute
Additional studies are planned to evaluate ifabotuzumab as part of an antibody-drug conjugate in various solid tumor types. Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2020 --> Mar 2021
- ifabotuzumab (KB004) / Humanigen
Preliminary findings of a phase I safety and bioimaging trial of KB004 (ifabotuzumab) in patients with glioblastoma. (Ballroom Lawn) - Oct 29, 2019 - Abstract #SNO2019SNO_966;
Most were considered related to study drug, seizures and infusion reactions were readily managed with increased premedications after the first occurrence. Best response in cohort 1 is SD for 23 weeks.
- ||| KB 002/003 / Humanigen, ifabotuzumab (KB004) / Humanigen, lenzilumab (KB003) / Humanigen
There were Mayo consultants on the published lists of Madoff investors, but I was thankfully not among them. Probably most "notorious" character I had direct contact with was "PharmaBro" Martin Shkreli, who was briefly CEO of KaloBios, developing KB003 and KB004 for CMML. (Twitter) - May 9, 2019
- | ifabotuzumab (KB004) / Humanigen
New P1 trial: A Trial of KB004 in Patients With Glioblastoma (clinicaltrials.gov) - Dec 18, 2017
P1, N=12, Recruiting, Sponsor: Olivia Newton-John Cancer Research Institute
- | ifabotuzumab (KB004) / Humanigen
Journal: KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study. (Pubmed Central) - Jul 21, 2017
Responses were observed in patients with AML, MF, MDS/MPN and MDS. In this study, KB004 was well tolerated and clinically active when given as a weekly infusion.
- | ifabotuzumab (KB004) / Humanigen
Trial suspension: Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF) (clinicaltrials.gov) - Nov 17, 2015
P1/2, N=120, Suspended, Sponsor: KaloBios Pharmaceuticals
In this study, KB004 was well tolerated and clinically active when given as a weekly infusion. Active, not recruiting --> Suspended
- ||| ifabotuzumab (KB004) / Humanigen
Enrollment closed: Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF) (clinicaltrials.gov) - Nov 15, 2015
P1/2, N=120, Active, not recruiting, Sponsor: KaloBios Pharmaceuticals
Active, not recruiting --> Suspended Recruiting --> Active, not recruiting
- ||| ifabotuzumab (KB004) / Humanigen
Enrollment change, Trial primary completion date: Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF) (clinicaltrials.gov) - Apr 8, 2015
P1/2, N=120, Recruiting, Sponsor: KaloBios Pharmaceuticals
Recruiting --> Active, not recruiting N=170 --> 120 | Trial primary completion date: Jul 2015 --> Jul 2016
- ||| ifabotuzumab (KB004) / Humanigen
Enrollment change: Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF) (clinicaltrials.gov) - Dec 3, 2013
P1/2, N=150, Recruiting, Sponsor: KaloBios Pharmaceuticals
N=170 --> 120 | Trial primary completion date: Jul 2015 --> Jul 2016 N=40 --> 150